{"schema_version":"secwatch.filing_event.v1","accession":"0001062822-24-000043","form_type":"8-K","ticker":"LXRX","cik":"0001062822","company_name":"LEXICON PHARMACEUTICALS, INC.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.064605+00:00","generated_at":"2026-05-31T13:37:31.027284+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexicon Q2 net loss $53.4M; INPEFA sales $1.6M; ZYNQUISTA NDA resubmitted","bullets":["Net loss $53.4M ($0.17/sh) vs $44.9M a year ago; cash & investments $310M, up from $170M.","INPEFA (sotagliflozin) net sales $1.6M; commercial launch ongoing.","NDA for ZYNQUISTA in type 1 diabetes resubmitted; PDUFA goal date Dec 20, 2024.","SONATA Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy commenced.","PROGRESS Phase 2b (LX9211) for DPNP topline data expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001062822-24-000043","json":"https://secwatch.observer/filing/0001062822-24-000043.json","markdown":"https://secwatch.observer/filing/0001062822-24-000043.md","text":"https://secwatch.observer/filing/0001062822-24-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000043/0001062822-24-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1062822/000106282224000043/lxrx-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:37:31.027284+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}